TRDA Entrada Therapeutics Inc

Price (delayed)

$6.995

Market cap

$271.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.99

Enterprise value

$241.56M

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 15
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 22

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, ...

Highlights
TRDA's debt is down by 13% YoY and by 2.3% from the previous quarter
TRDA's quick ratio is down by 36% year-on-year but it is up by 10% since the previous quarter
The gross profit has dropped by 97% year-on-year and by 77% since the previous quarter
Entrada Therapeutics's revenue has plunged by 97% YoY and by 77% from the previous quarter

Key stats

What are the main financial stats of TRDA

TRDA stock price

How has the Entrada Therapeutics stock price performed over time
Intraday
6.31%
1 week
2.57%
1 month
-55.7%
1 year
-11.79%
YTD
-31.96%
QTD
-44.57%

Financial performance

How have Entrada Therapeutics's revenue and profit performed over time
Revenue
$5.74M
Gross profit
$5.74M
Operating income
-$178.41M
Net income
-$166.12M
Gross margin
100%
Net margin
-2,895.1%
The gross profit has dropped by 97% year-on-year and by 77% since the previous quarter
Entrada Therapeutics's revenue has plunged by 97% YoY and by 77% from the previous quarter
TRDA's net income is down by 16% QoQ
The operating income is down by 13% since the previous quarter

Price vs fundamentals

How does TRDA's price correlate with its fundamentals

Growth

What is Entrada Therapeutics's growth rate over time

Valuation

What is Entrada Therapeutics stock price valuation
P/E
N/A
P/B
0.99
P/S
51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
42.1
TRDA's EPS is down by 15% from the previous quarter
TRDA's price to book (P/B) is 42% lower than its 5-year quarterly average of 1.6 and 15% lower than its last 4 quarters average of 1.1
The equity has contracted by 35% YoY and by 12% from the previous quarter
Entrada Therapeutics's revenue has plunged by 97% YoY and by 77% from the previous quarter
The stock's P/S is 65% more than its last 4 quarters average of 29.0

Efficiency

How efficient is Entrada Therapeutics business performance
The ROIC has declined by 30% since the previous quarter
Entrada Therapeutics's return on equity has decreased by 29% QoQ
Entrada Therapeutics's return on assets has decreased by 27% QoQ

Dividends

What is TRDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TRDA.

Financial health

How did Entrada Therapeutics financials performed over time
TRDA's quick ratio is down by 36% year-on-year but it is up by 10% since the previous quarter
Entrada Therapeutics's current ratio has decreased by 36% YoY but it has increased by 11% QoQ
TRDA's debt is 82% less than its equity
The equity has contracted by 35% YoY and by 12% from the previous quarter
Entrada Therapeutics's debt to equity has increased by 29% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.